Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, erasing what had been ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

Siren emerges from stealth with plans to marry gene therapy to cancer immunotherapy Spun out of the lab of former UCSF researcher Nicole Paulk, the biotech is targeting brain and eye tumors with a new ...

Novartis will spend $300 million to bolster its development and production capabilities for biologic medicines, which make up an increasing share of its drug pipeline. The Swiss drugmaker will invest ...

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...